The 9th Antifibrotic Drug Development Summit stands as the premier industry-driven forum bringing together drug developers across IPF, MASH, systemic sclerosis, and kidney, cardiac, and gastrointestinal fibrosis to address common challenges from early discovery through Phase 2.

Download the agenda to explore 25+ sessions, including deep-dive workshops on chronic fibrosis modeling, clinical case studies, and panels debating post-GLP-1 positioning. Connect with 80+ attendees from Pfizer, Novartis, and GSK, and discover how to align your program with pharma’s $1B+ licensing appetite.